Reading between the lines of what the company has been saying I think the results that will be announced will be good. There are two key issues to focus on - whether they have some alternative imaging results to back up their bone scans to show they aren't somehow artifactual, and whether the investigator-sponsored study can show some pain results with lower doses.
So I think this may be a reasonable short-term trade whatever one might think of their long-term prospects.
Market Data 
Markets 
AI
